Go Pro
NASDAQ:CLGN

CollPlant Biotechnologies Q2 2026 Earnings Report

CollPlant Biotechnologies logo
$3.46 -0.11 (-3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$3.60 +0.14 (+3.90%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CollPlant Biotechnologies EPS Results

Actual EPS
-$1.89
Consensus EPS
-$2.45
Beat/Miss
Beat by +$0.56
One Year Ago EPS
N/A

CollPlant Biotechnologies Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.48 million
Beat/Miss
Missed by -$372.00 thousand
YoY Revenue Growth
N/A

CollPlant Biotechnologies Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CollPlant Biotechnologies' Q2 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedules

Conference Call Resources

CollPlant Biotechnologies Earnings Headlines

CollPlant Biotechnologies Q2 Net Loss Narrows
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.tc pixel
See More CollPlant Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CollPlant Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CollPlant Biotechnologies and other key companies, straight to your email.

About CollPlant Biotechnologies

CollPlant Biotechnologies (NASDAQ:CLGN) Ltd. is an Israel-based regenerative medicine company developing products based on recombinant human collagen (rhCollagen). The company produces rhCollagen using genetically engineered tobacco plants, an approach designed to create collagen with consistent properties and without relying on animal or human tissues.

CollPlant’s technology is intended for use in tissue regeneration, medical aesthetics, wound care and organ manufacturing. Its product portfolio includes rhCollagen-based biomaterials and bioinks for three-dimensional bioprinting, which are designed to support the development of implants, tissue scaffolds and other regenerative medicine applications.

Founded in 2004 and headquartered in Rehovot, Israel, CollPlant has pursued collaborations and licensing arrangements with companies in the medical technology and bioprinting industries. The company serves global markets through partnerships and the development of technologies for pharmaceutical, medical device and tissue-engineering applications.

View CollPlant Biotechnologies Profile